Valneva IPO Presentation Deck

Phase 1 Trial Led to Direct Progression into Phase 3 ■ Observer-blinded, randomized, multicenter, dose escalation study ■ Study Population: 120 healthy volunteers aged 18 to 45 years 50 ■ Dosage: 3.2x10³ TCID 50 (0.1ml), 3.2x104 TCID (1ml), 3.2x105 TCID50 (1ml) ■ Immunization route: intramuscular SCREENING PART A Sample Size N = 120 Day/M -21 Study Arm L R Study Arm M H Study Arm H **** 0 28/M1 Valneva - Roadshow Presentation Dose: 3.2x10³/0.1mL PART B Dose: 3.2x104/1mL Dose: 3.2x105 / 1mL 84/M3 Safety including viremia on Days 0/3/7/14 post-vaccination N=30 N=30 N=60 R RYT Study Arm H1 Study Arm H2 180/M6 M7 ***** PART C N=30 N=30 M12 D COD- **** V M13 Re-vaccination at Month 6 and 12 with the highest dose (homologous viral challenge) April 2021 19

View entire presentation